Borgeson Blake

SEC Form 4 insider trading activity

Borgeson Blake has filed 11 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 11 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.

On the most recent filing, Borgeson Blake is listed as Director at RECURSION PHARMACEUTICALS, INC. Inside the rolling window, Borgeson Blake reported no open-market purchases and 10 open-market sales totaling $4.1M in RXRX. The largest disclosed transaction in the window is a sale of 220,000 RXRX shares on Dec 2, 2025, worth $961K.

Companies traded

Other insiders at RXRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$4.1M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
RXRXSale$100KSep 2SEC ↗
RXRXSale$98KAug 6SEC ↗
RXRXSale$159KJul 9SEC ↗
RXRXSale$110KJun 4SEC ↗
RXRXSale$106KMay 7SEC ↗
RXRXSale$93KApr 8SEC ↗
RXRXSale$588KMar 4SEC ↗
RXRXSale$924KFeb 6SEC ↗
RXRXSale$959KJan 8SEC ↗
RXRXSale$961KDec 4SEC ↗

Frequently asked questions

How many SEC Form 4 filings has Borgeson Blake made?

Borgeson Blake has filed 11 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.

Which companies does Borgeson Blake trade?

Borgeson Blake has filed SEC Form 4 disclosures for 1 company, including RXRX.

When was Borgeson Blake's most recent SEC Form 4 filing?

Borgeson Blake's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.

What is Borgeson Blake's total buy and sell value in the current window?

Inside the rolling retention window, Borgeson Blake bought $0 and sold $4.1M based on SEC Form 4 filings.

What was Borgeson Blake's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 220,000 RXRX shares on 2025-12-02, worth $961K, per SEC Form 4 filings.